Modalis Therapeutics Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Net Income	-	-1,316	-2,390	-2,707	-745	-439	Upgrade
Depreciation & Amortization	-	-	-	123	77	57	Upgrade
Loss (Gain) From Sale of Assets	-	-	38	997	2	-	Upgrade
Other Operating Activities	-	-15	1	1	488	-	Upgrade
Change in Accounts Receivable	-	-	-	-	-	6	Upgrade
Change in Accounts Payable	-	-119	49	9	51	-31	Upgrade
Change in Other Net Operating Assets	-	18	48	-318	-620	31	Upgrade
Operating Cash Flow	-	-1,432	-2,254	-1,895	-747	-376	Upgrade
Capital Expenditures	-	-	-39	-197	-107	-16	Upgrade
Sale (Purchase) of Intangibles	-	-	-	-	-	-814	Upgrade
Other Investing Activities	-	-	-	12	278	-	Upgrade
Investing Cash Flow	-	-	-39	-185	171	-830	Upgrade
Long-Term Debt Issued	-	694	488	-	-	-	Upgrade
Long-Term Debt Repaid	-	-37	-	-	-	-	Upgrade
Net Debt Issued (Repaid)	-	657	488	-	-	-	Upgrade
Issuance of Common Stock	-	2,395	735	71	72	2,798	Upgrade
Other Financing Activities	-	-8	-7	-8	-	-21	Upgrade
Financing Cash Flow	-	3,044	1,216	63	72	2,777	Upgrade
Foreign Exchange Rate Adjustments	-	79	27	14	17	-6	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	1	-	2	-1	Upgrade
Net Cash Flow	-	1,691	-1,049	-2,003	-485	1,564	Upgrade
Free Cash Flow	-	-1,432	-2,293	-2,092	-854	-392	Upgrade
Free Cash Flow Margin	-	-	-	-5230.00%	-85400.00%	-114.62%	Upgrade
Free Cash Flow Per Share	-	-31.05	-74.05	-71.87	-29.70	-14.88	Upgrade
Cash Interest Paid	-	3	4	6	-	-	Upgrade
Cash Income Tax Paid	-	1	1	1	1	-	Upgrade
Levered Free Cash Flow	-	-890.63	-1,418	-1,402	-787	-1,065	Upgrade
Unlevered Free Cash Flow	-	-885.63	-1,408	-1,399	-786.38	-1,065	Upgrade
Change in Net Working Capital	-216.55	50	-112	36	-18	43	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.